

Brain–Computer Interfaces for Treatment of Focal Dystonia

Kristina Simonyan, MD, PhD, DrMed,^{1,2*} Stefan K. Ehrlich, PhD,¹ Richard Andersen, PhD,³ Jonathan Brumberg, PhD,⁴ Frank Guenther, PhD,^{5,6,7,8} Mark Hallett, MD,⁹ Matthew A. Howard, MD,¹⁰ José del R. Millán, PhD,^{11,12} Richard B. Reilly, PhD,¹³ Tanja Schultz, Dr-Ing,¹⁴ and Davide Valeriani, PhD¹

¹Department of Otolaryngology–Head and Neck Surgery, Massachusetts Eye and Ear and Harvard Medical School, Boston, Massachusetts, USA

²Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA

³Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA

⁴Department of Speech–Language–Hearing: Sciences & Disorders, University of Kansas, Lawrence, Kansas, USA

⁵Department of Speech, Language, & Hearing Sciences, Boston University, Boston, Massachusetts, USA

⁶Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA

⁷Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA

⁸Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

⁹Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

¹⁰Department of Neurosurgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

¹¹Department of Electrical and Computer Engineering, University of Texas at Austin, Austin, Texas, USA

¹²Department of Neurology, University of Texas at Austin, Austin, Texas, USA

¹³Center for Biomedical Engineering, Trinity College Institute of Neuroscience, School of Medicine, School of Engineering, Trinity College Dublin and the University of Dublin, Dublin, Ireland

¹⁴Faculty 03 Mathematics and Computer Science, University of Bremen, Bremen, Germany

Isolated dystonia is a debilitating disorder that causes involuntary muscle contractions leading to abnormal, often repetitive, and sometimes painful movements. Typically, symptoms develop midlife and take a toll not only on the freedom of movement but also the various aspects of the individual's life, causing social embarrassment, derailed professional careers, chronic stress, psychiatric comorbidities, and increased suicidal risk.^{1,2} Despite the significant progress made in the past decades toward understanding genetic, cellular, and neural mechanisms underlying dystonia pathophysiology, its treatment remains stagnant.^{3,4} Therapeutic options are largely limited to temporary symptom management with botulinum toxin injections into the affected muscles; selective oral medications are nonexistent, and the off-label use of new drugs is restricted to trial-and-error explorations. Invasive neuromodulation with deep brain stimulation of globus pallidus and, more recently, magnetic resonance–guided

focused ultrasound thalamotomy shows therapeutic benefits; however, only a fraction of patients with isolated dystonia undergoes brain surgery.^{5,6}

The continuous gaps in the understanding of the ever-evolving complexity of dystonia pathophysiology were partly to blame for the lack of development of adequate treatments.^{3,4} Traditionally, isolated dystonia was considered a basal ganglia disorder because of the predilection for striatal lesions to trigger dystonic symptoms.⁷ According to the basal ganglia model of dystonia, an imbalance of the direct and indirect pathways was thought to underlie bottom-up abnormal decreases of intracortical inhibition and subsequent increases of cortical motor excitability.^{8–10} Another model of dystonia has focused on the cerebellum, which was reported as one of the common sites of lesions causing secondary dystonia, proposing that cerebellar alterations may also be causal in the pathophysiology of isolated dystonia.^{11,12} Although both the basal ganglia and cerebellum are critically important structures, clarifications of their involvement in dystonia pathophysiology have not yet, regrettably, led to breakthroughs in the treatment of these patients.

In parallel, advanced neuroimaging studies unveiled a more complex, larger-scale brain disorganization in dystonia. Following original studies that mapped the abnormal metabolic network in generalized dystonia,^{9,13} recent research determined that focal dystonias are functional and structural neural network disorders where alterations in basal ganglia, cerebellar,

© 2022 International Parkinson and Movement Disorder Society.

*Correspondence to: Prof. K. Simonyan, Department of Otolaryngology–Head and Neck Surgery, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles Street, Suite 421, Boston, MA 02114, USA; E-mail: kristina_simonyan@meei.harvard.edu

Relevant conflicts of interest/financial disclosures: Nothing to report.

Received: 28 March 2022; **Revised:** 20 June 2022; **Accepted:** 19 July 2022

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29178

and cortical sensorimotor and frontoparietal regions are critical components of the dystonic network^{14,15} (Fig. 1). According to the currently prevailing network model of the disorder, the basal ganglia, thalamus, and cerebellum are at the core of network aberrations across all forms of dystonia. In parallel, phenotypically and genotypically different forms of dystonia are characterized by widespread but form-specific abnormalities in cortical regions responsible for multisensory processing, sensorimotor integration, and motor execution. Among these, the neural signature of task-specific dystonias, such as laryngeal dystonia, writer's cramp, or musician's dystonia, includes significant alterations in primary sensorimotor, premotor, and inferior parietal cortical areas compared with predominantly subcortical changes in non-task-specific dystonias, such as cervical dystonia or blepharospasm.^{16,17}

Collectively, these studies expanded our understanding of dystonia pathophysiology beyond the basal ganglia and cerebellum, leading to the recommendation by the 2018 National Institutes of Health/National Institute of Neurological Disorders and Stroke Working Group on Dystonia Research Priorities to target well-defined network abnormalities that are commonly shared across different forms for the formulation of effective therapeutic strategies.¹⁸ This Viewpoint




FIG. 1. Simplified schematic of functional and structural neural network alterations in focal dystonia. Colored areas depict cortical targets of neurofeedback brain-computer interface (BCI) intervention; gray areas depict other critical regions within the dystonic neural network. Alterations in inferior parietal (IPC) and premotor (PreM) cortex are thought to precede and influence those in the primary sensorimotor cortex (M1/S1). It is expected that BCI-based modulation of IPC-PreM activity leads to attenuation of M1/S1 activity, which, in turn, results in normalized M1/S1 output, including to the basal ganglia (BG) and cerebellum (Cbl). Solid black arrows indicate cortical sensorimotor modulation directly targeted by the proposed neurofeedback BCI intervention; dashed arrows indicate downstream effects resulting from cortical modulation. IFG, inferior frontal gyrus; MFG, middle frontal gyrus; OC, occipital cortex; SMA, supplementary motor area; SPC, superior parietal cortex; Th, thalamus.

outlines the consensus outcome of a multidisciplinary panel of experts from the fields of neurology, neurosurgery, neuroscience, speech sciences, engineering, and computer sciences who met within the framework of the Radcliffe Institute for Advanced Study at Harvard University in September 2020 to review the current state of knowledge of dystonia pathophysiology with the aim to formulate novel therapeutic interventions using advanced brain-computer interfaces (BCIs). The expert panel identified a well-known clinical phenomenon of task specificity in focal dystonias as a powerful pathophysiological feature that may successfully be targeted with BCIs and outlined the roadmap for implementing this neurotechnology for the treatment of patients with focal task-specific dystonias.

BCIs and Neurofeedback Intervention

BCIs are devices designed to record brain activity, extract information from neural signals, and use this information to manipulate an effector.¹⁹ Neural signals are translated into a control signal, which, in turn, drives an effector that is fed back perceptually to the user. Much of the pioneering BCI research has focused on providing new communication tools to patients with severe motor impairments (eg, locked-in syndrome) who progressively lose their ability for verbal and non-verbal communication.²⁰⁻²³ Recently, the first closed-loop speech neuroprosthesis has been developed, which reconstructed, without delay, neural signals of imagined speech into an audio signal, allowing patients to hear what they imagined speaking.²⁴ Other prominent examples include deriving directional control signals to steer a computer cursor or robotic systems for giving autonomy to patients suffering from motor disabilities as a result of spinal cord injury and other conditions.^{25,26} The key aspect of these BCIs is the closed-loop paradigm, where the feedback represents the momentary brain activity of the user and follows changes in neural activity associated with the given behavior. When provided with sufficient training, these adaptive BCIs enable the user to gain voluntary control over their neural activity and learn to self-regulate their brain activity.¹⁹ Notably, neurofeedback serves as a form of endogenous neural stimulation,^{27,28} helping the user refine momentary brain activity for the most optimal behavioral outcome.

Various BCIs have been studied for their potential in the rehabilitation of neurological disorders affecting the sensorimotor system,^{27,29} such as restoring motor function following stroke,^{30,31} Parkinson's disease,^{32,33} and essential tremor.³⁴ Largely missing from this literature are BCIs for patients with isolated dystonia. To date, only one case report using the electroencephalography

(EEG)-based BCI has been published in a patient with writer's cramp.³⁵ Using visual feedback, this patient was trained to suppress abnormal cortical sensorimotor activity in the beta-frequency band during repetitive hand extensions. After 10 training sessions, the patient showed a significant reduction of dystonic symptoms, which was associated with decreased beta band event-related synchronization. Despite limited data, this proof-of-concept study pointed to the feasibility of BCIs for dystonia treatment.

Other relevant studies include the use of different feedback paradigms, eg, visual-haptic biofeedback, auditory grip force feedback, and reversal-learning tasks, for improved motor control in patients with focal hand dystonia and children with dystonia.^{36,37} Although these feedback paradigms were not used as BCI components, these studies demonstrated that continuous sensorimotor training may translate into effective rehabilitation strategies for patients with dystonia, possibly by inducing plastic cortical reorganization and adaptation.¹⁸

A Roadmap for BCI-Based Therapeutic Strategies for Focal Task-Specific Dystonias

One of the prerequisites for effective implementation of neurofeedback BCIs for dystonia treatment is the targeting of the disorder's pathophysiological neural signature. Patients with task-specific focal dystonias are ideal candidates for developing personalized BCI protocols because of their unique clinical feature of a *selective* motor program impairment, which allows to reliably distinguish neural activity associated with symptomatic versus asymptomatic behaviors. In such BCIs, we define individual abnormal brain activity during symptomatic task production as the *disorder signature* and close-to-

normal brain activity during an asymptomatic but relevant motor task as the *target signature*. Both disorder and target signatures are constructed based on EEG activity from cortical regions whose alterations are known to play an important role in task-specificity of focal dystonias. Specifically, prior studies have been consistent in showing abnormalities in premotor-parietal activity as one of the prominent neural features of task-specificity across different forms of focal dystonia.^{38,39} Moreover, premotor-parietal alterations appear to *precede* and influence the output of dystonic activity by primary motor cortex.⁴⁰ We therefore anticipate that targeted modulation of premotor-parietal activity with the neurofeedback BCI would normalize the information flow from these regions to primary sensorimotor cortex, which, in turn, would attenuate motocortical hyperexcitability (first-order modulation) and subsequently reduce abnormal motocortical output within the larger dystonic network, including to subcortical structures, such as the basal ganglia and cerebellum (second-order modulation) (Fig. 1).

In this article, we outline a recommendation for a noninvasive, closed-loop neurofeedback BCI intervention paradigm in an example of laryngeal dystonia, isolated focal task-specific dystonia selectively affecting the production of voiced, but not whispered, speech. The integrated components of this BCI include: (1) a high-density EEG acquisition system, which records cortical activity for constructing individual neurofeedback and (2) a built-in machine learning (ML) platform consisting of a neural signal decoder and a neurofeedback controller that (3) provide visual feedback of ongoing EEG activity to the patient in near real time, eg, via a computer screen or virtual reality environment (Fig. 2A). Before the BCI intervention, the individual target signature is constructed based on the EEG recording of close-to-normal cortical activity during asymptomatic whisper. During the BCI intervention,




FIG. 2. (A) Overview of the neurofeedback BCI paradigm for treatment of focal task-specific dystonia, including a high-density EEG recording system, an ML-BCI platform, and a visual neurofeedback monitoring system. The ML-BCI platform transforms the momentary EEG activity into continuous visual neurofeedback that is based on the difference between the transient disorder signature and the target signature. While performing a symptomatic task, the patient actively regulates their brain activity to match the disorder signature to the target signature of a related but asymptomatic motor task. (B) Throughout the BCI training, the disorder signature is expected to gradually correspond to the target signature, which, in turn, is expected to be associated with clinically relevant symptom reduction. BCI, brain-computer interface; EEG, electroencephalography; ML, machine learning.

ongoing EEG activity during symptomatic speaking constitutes the individual disorder signature, which is continuously fed to the ML-BCI platform for computing the delta change from the target signature. The signal difference between disorder and target signatures is delivered to the patient in near real time as visual neurofeedback for guiding the dynamic learning process. That is, throughout the BCI intervention session, the patient learns to modulate their disorder signature associated with symptomatic speaking and normalize it to the level of the target signature associated with asymptomatic whisper (Fig. 2B). Such BCI-based modulation of brain activity is expected to translate to clinically relevant symptom reduction.

Similar neurofeedback BCI designs may be adapted for other forms of focal task-specific dystonia. For example, patients with writer's cramp may use their neural activity during symptomatic writing as the disorder signature and asymptomatic tapping as the target signature. Depending on the form of dystonia, personalized ML-BCI platforms should be calibrated based on individual alterations in EEG frequency bands and other pathophysiologically relevant neural and behavioral features. Other important methodological considerations include robust correction of EEG motion artifacts associated with the production of complex motor behaviors, eg, speaking or writing. In this context, the use of high-density EEG would allow to exclude peripheral, motion-prone electrodes during signal processing without compromising sufficient density of signal sampling from cortical regions of pathophysiological relevance. Moreover, high-density EEG effectively separates potential artifacts from relevant signal components using source and subspace reconstruction techniques.

To rigorously assess the outcome of neurofeedback BCIs and reduce the possibility of a training bias, the BCI interventions in patients with dystonia should consider the incorporation of a sham condition, eg, in the form of random neurofeedback. Longitudinal study designs are preferred to monitor changes in symptoms during and after BCI intervention. Finally, because of the lack of consensus on the outcome measures in dystonia, it is important to implement both objective and subjective evaluations using the clinician-administered standardized dystonia rating scales and patient self-ratings of their current state of symptoms, respectively.

Conclusion and Future Directions

Given the breadth of previous research on neurofeedback BCIs with promising outcomes in other neurological disorders, recent developments in neural decoding methods, existing computational capabilities for neural signal processing in near real time, and the

current state of knowledge of clinical features and pathophysiology of dystonia, we propose that it is timely to develop and implement adaptive neurofeedback BCI interventions for the treatment of these patients. One such closed-loop BCI system that leverages the disorder's clinical and pathophysiological characteristics by targeting the task-specificity of focal dystonia is described earlier.

We recognize that patients with task-specific focal dystonias would likely receive greater benefits from the recommended BCI intervention paradigm than those with generalized or non-task-specific dystonias. We, however, expect this article to facilitate a broader discussion across the field for further development of BCIs in patients with various other forms of dystonia.

Future research should also be directed to ensuring the maintenance of BCI therapeutic benefits for the long-term clinical management of these patients. Although high-density EEG and other research-grade systems offer high precision for identifying clinically relevant pathophysiological features of significant therapeutic potential, they are challenging to use in the clinical setting. Therefore, building on the outcomes of research BCI studies, the ultimate goal should be to transfer the effective research technology to clinically applicable solutions. One such implementation may be the development of in-home-use portable devices with fewer electrodes and simplified setup procedures. Other opportunities may include developing implantable BCI devices or integrating the novel sensing deep brain stimulation systems (eg, Medtronic Percept PC) with neurofeedback BCIs for delivering patient-specific therapeutic benefits. ■

Acknowledgments: We thank Dr. Tonio Ball for his initial discussions on the topic of this Viewpoint. This work was supported by funding from the Radcliffe Institute for Advanced Study at Harvard University (to K.S. and D.V.) and the National Institute on Deafness and Other Communication Disorders, National Institutes of Health (grants R01DC012545 and R01DC019353 to K.S.).

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study

References

1. Conte A, Rocchi L, Latorre A, Belvisi D, Rothwell JC, Berardelli A. Ten-year reflections on the neurophysiological abnormalities of focal dystonias in humans. *Mov Disord* 2019;34(11):1616–1628.
2. Worthley A, Simonyan K. Suicidal ideations and attempts in patients with isolated dystonia. *Neurology* 2021;96(11):e1551–e1560
3. Termsarasab P, Thammongkolchai T, Frucht SJ. Medical treatment of dystonia. *J Clin Mov Disord* 2016;3:19
4. Balint B, Mencacci NE, Valente EM, et al. Dystonia. *Nat Rev Dis Primers* 2018;4(1):25

5. Vidailhet M, Jutras M-F, Roze E, Grabli D. Deep brain stimulation for dystonia. *Handb Clin Neurol* 2013;116:167–187.
6. Ortiz RM, Scheperjans F, Pekkonen E. Deep brain stimulation for dystonia in Finland during 2007–2016. *BMC Neurol* 2019;19(1):137
7. Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. *Brain* 1985;108(Pt 2):463–483.
8. Hallett M. Physiology of basal ganglia disorders: an overview. *Can J Neurol Sci* 1993;20(3):177–183.
9. Eidelberg D, Moeller JR, Ishikawa T, et al. The metabolic topography of idiopathic torsion dystonia. *Brain* 1995;118(Pt 6):1473–1484.
10. Simonyan K, Cho H, Hamzehei Sichani A, Rubien-Thomas E, Hallett M. The direct basal ganglia pathway is hyperfunctional in focal dystonia. *Brain* 2017;140(12):3179–3190.
11. Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. *J Neurosci* 2009;29(31):9740–9747.
12. Prudente CN, Hess EJ, Jinnah HA. Dystonia as a network disorder: what is the role of the cerebellum? *Neuroscience* 2014;260:23–35.
13. Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. *Ann Neurol* 1998;44(3):303–312.
14. Battistella G, Termsarasab P, Ramdhani RA, Fuertinger S, Simonyan K. Isolated focal dystonia as a disorder of large-scale functional networks. *Cereb Cortex* 2017;27(2):1203–1215.
15. Hanekamp S, Simonyan K. The large-scale structural connectome of task-specific focal dystonia. *Hum Brain Mapp* 2020;41(12):3253–3265.
16. Tomić A, Agosta F, Sarasso E, et al. Brain structural changes in focal dystonia – what about task specificity? A multimodal MRI study. *Mov Disord* 2021;36(1):196–205.
17. Ramdhani RA, Kumar V, Velickovic M, Frucht SJ, Tagliati M, Simonyan K. What's special about task in dystonia? A voxel-based morphometry and diffusion weighted imaging study. *Mov Disord* 2014;29(9):1141–1150.
18. Lungu C, Ozelius L, Standaert D, et al. Defining research priorities in dystonia. *Neurology* 2020;94(12):526–537.
19. Wolpaw JR, Millán JDR, Ramsey NF. Brain-computer interfaces: definitions and principles. *Handb Clin Neurol* 2020;168:15–23.
20. Andersen RA, Aflalo T, Kellis S. From thought to action: the brain-machine interface in posterior parietal cortex. *Proc Natl Acad Sci* 2019;116(52):26274–26279.
21. Willett FR, Avansino DT, Hochberg LR, Henderson JM, Shenoy KV. High-performance brain-to-text communication via handwriting. *Nature* 2021;593(7858):249–254.
22. Brumberg JS, Nieto-Castanon A, Kennedy PR, Guenther FH. Brain-computer interfaces for speech communication. *Speech Commun* 2010;52(4):367–379.
23. Herff C, Heger D, de Pestors A, et al. Brain-to-text: decoding spoken phrases from phone representations in the brain. *Front Neurosci* 2015;9:217
24. Angrick M, Ottenhoff MC, Diener L, et al. Real-time synthesis of imagined speech processes from minimally invasive recordings of neural activity. *Commun Biol* 2021;4(1):1055
25. Collinger JL, Wodlinger B, Downey JE, et al. High-performance neuroprosthetic control by an individual with tetraplegia. *Lancet* 2013;381(9866):557–564.
26. Perdakis S, Tonin L, Saedi S, Schneider C, Millán JDR. The Cybathlon BCI race: successful longitudinal mutual learning with two tetraplegic users. *PLoS Biol* 2018;16(5):e2003787
27. Sitaram R, Ros T, Stoeckel L, et al. Closed-loop brain training: the science of neurofeedback. *Nat Rev Neurosci* 2017;18(2):86–100.
28. Flor H, Diers M. Sensorimotor training and cortical reorganization. *NeuroRehabilitation* 2009;25(1):19–27.
29. Daly JJ, Huggins JE. Brain-computer interface: current and emerging rehabilitation applications. *Arch Phys Med Rehabil* 2015;96(3 Suppl):S1–S7.
30. Biasucci A, Leeb R, Iturrate I, et al. Brain-actuated functional electrical stimulation elicits lasting arm motor recovery after stroke. *Nat Commun* 2018;9(1):2421
31. Cervera MA, Soekadar SR, Ushiba J, et al. Brain-computer interfaces for post-stroke motor rehabilitation: a meta-analysis. *Ann Clin Transl Neurol* 2018;5(5):651–663.
32. Miladinovic A, Ajcevic M, Busan P, et al. Evaluation of motor imagery-based BCI methods in neurorehabilitation of Parkinson's disease patients. *Annu Int Conf IEEE Eng Med Biol Soc* 2020;2020:3058–3061.
33. Little S, Pogosyan A, Neal S, et al. Adaptive deep brain stimulation in advanced Parkinson disease. *Ann Neurol* 2013;74(3):449–457.
34. Rocon E, Gallego JA, Barrios L, et al. Multimodal BCI-mediated FES suppression of pathological tremor. *Annu Int Conf IEEE Eng Med Biol Soc* 2010;2010:3337–3340.
35. Hashimoto Y, Ota T, Mukaino M, Liu M, Ushiba J. Functional recovery from chronic writer's cramp by brain-computer interface rehabilitation: a case report. *BMC Neurosci* 2014;15:103
36. Atashzar SF, Shahbazi M, Ward C, et al. Haptic feedback manipulation during botulinum toxin injection therapy for focal hand dystonia patients: a possible new assistive strategy. *IEEE Trans Haptics* 2016;9(4):523–535.
37. Casellato C, Pedrocchi A, Zorzi G, Vernisse L, Ferrigno G, Nardocci N. EMG-based visual-haptic biofeedback: a tool to improve motor control in children with primary dystonia. *IEEE Trans Neural Syst Rehabil Eng* 2013;21(3):474–480.
38. Gallea C, Horovitz SG, Ali Najee-Ullah M, Hallett M. Impairment of a parieto-premotor network specialized for handwriting in writer's cramp. *Hum Brain Mapp* 2016;37(12):4363–4375.
39. Bianchi S, Fuertinger S, Huddleston H, Frucht SJ, Simonyan K. Functional and structural neural bases of task specificity in isolated focal dystonia. *Mov Disord* 2019;34(4):555–563.
40. Battistella G, Simonyan K. Top-down alteration of functional connectivity within the sensorimotor network in focal dystonia. *Neurology* 2019;92(16):e1843–e1851.

SGML and CITI Use Only
DO NOT PRINT

Author Roles

Study concept and design – K.S., D.V., and S.K.E.; Drafting the manuscript – S.K.E. and K.S.; Discussion of the paper – K.S., S.K.E., R.A., J.B., F.G., M.H., M.A.H., J.d.R.M., R.B.R., T.S., and D.V.; Revising the manuscript – K.S., S.K.E., D.V., R.A., J.B., F.G., M.H., M.A.H., J.d.R.M., R.B.R., and T.S.; Obtaining funding – K.S.

Financial Disclosures

M.H. is an inventor of a patent held by the National Institutes of Health (NIH) for the H-coil for magnetic stimulation for which he receives license fee payments from the NIH (from Brainsway). He is on the Medical Advisory Boards of CALA Health and Brainsway (both unpaid positions). He has a research grant from Medtronic, Inc., for a study of deep brain stimulation for dystonia. D.V. is an employee at Neurable, Inc. K.S. receives funding from the NIH (R01NS088160, R01DC011805, R01DC012545, R01DC019353, R01NS014228, and P50DC019900), the Department of Defense (W911NF1810434), and Amazon Web Services; receives consulting fees from Jazz Pharmaceuticals and AbbVie; and serves on the Scientific Advisory Boards of the Tourette Association of America and the Voice Foundation (both unpaid positions).